期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 53, 期 3, 页码 211-224出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2018.10.011
关键词
Ceftolozane/tazobactam; Ceftazidime/avibactam; Meropenem/vaborbactam; Plazomicin; Eravacycline; Multidrug-resistant Gram-negative bacteria
The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire and spread new resistance mechanisms. Treating infections caused by Gram-negative bacteria is a challenge for medical practitioners and increases patient mortality and cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development, prompts the development of new antibiotic agents and exploration of alternative treatment options. This article summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues that show potential in combating multidrug-resistant Gram-negative bacteria. (c) 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据